ICOS Corporation Selects Dendrite To Develop Company's New SFA System
Growing Biotechnology Company To Build Sales and Marketing Capabilities Using Dendrite Solutions
MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 31, 2002--Dendrite (NASDAQ/NMS: DRTE - news) today announced that ICOS Corporation (NASDAQ:ICOS - news) has chosen Dendrite to play a strategic role in establishing its U.S. sales force.
Under a recent agreement, Dendrite will develop ICOS' new Sales Force Automation (SFA) system. ICOS field representatives, managers, and home office personnel will deploy a broad range of Dendrite's innovative sales force automation (SFA) solutions. These include WebForce(TM), ForceMobile(TM), ForceAdministrator(TM), ForceAnalyzer(TM), and Validator(TM).
The contract also includes a complete services agreement, under which Dendrite will provide training and implementation, customer support, as well as hardware and data center services.
``ICOS has an expanding pipeline of product candidates, and we expect our sales and marketing requirements to evolve quickly,'' said ICOS Chairman and CEO Paul Clark. ``We are building a leading sales force. That requires innovative technology to gain a stronghold in the marketplace. Dendrite's solutions and services should meet both our near- and our longer-term sales force requirements.''
Bob Parisi, Dendrite Group President, Domestic Market, added, ``While Dendrite works with the world's largest biotechnology and pharmaceutical companies, we also have extensive experience and expertise in developing solutions and services that meet specific requirements of emerging companies such as ICOS. We believe that by developing a new SFA solution, we can truly partner with ICOS from the ground up to help them achieve both their short- and long-term sales and marketing objectives.''
Dendrite Solutions
To maximize sales force productivity, ICOS will utilize the following Dendrite solutions:
WebForce(TM): a comprehensive, web-enabled product suite that improves communications, optimizes promotional activities, and streamlines new product launches.
ForceMobile(TM): a complete biotech/pharmaceutical sales force solution designed specifically for use with handheld devices.
ForceAdministrator(TM): an interactive territory-management tool that enables companies to manage product, user, and alignment field force changes.
ForceAnalyzer(TM): a flexible, easy-to-use data viewing and analysis tool that enables field representatives and management to track the effects of promotional activities, achieve sales objectives, assure call-plan compliance, and manage promotional program implementation.
Validator(TM): verifies and validates prescribers by license data to ensure that field forces sample only valid prescribers; scrubs data to keep it current and accurate.
About ICOS Corporation
Based in Bothell, Washington, ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The company combines its capabilities in molecular, cellular, and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential.
The company applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases, and inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing the company's opportunities for marketing breakthrough products. For more information, visit www.icos.com.
About Dendrite
Dendrite, the visionary innovator in global pharmaceutical technology, helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as ``expect,'' ``believe,'' ``may,'' ``will,'' ``intend,'' ``plan,'' and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Ogilvy Public Relations Worldwide, New York
Bob Brody, 212/880-5248
Bob.Brody@ogilvypr.com |
